Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species - PubMed (original) (raw)
. 2005 Feb 15;105(4):1717-23.
doi: 10.1182/blood-2004-03-0849. Epub 2004 Oct 14.
Affiliations
- PMID: 15486067
- DOI: 10.1182/blood-2004-03-0849
Free article
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species
Jeong H Kim et al. Blood. 2005.
Free article
Abstract
BCR-ABL oncoprotein-expressing cells are associated with a relative increase of intracellular reactive oxygen species (ROS), which is thought to play a role in transformation. Elevated ROS levels in BCR-ABL-transformed cells were found to be blocked by the mitochondrial complex I inhibitor rotenone as well as the glucose transport inhibitor phloretin, suggesting that the source of increased ROS might be related to increased glucose metabolism. The glucose analog 2-deoxyglucose (2-DOG) reduced ROS to levels found in non-BCR-ABL-transformed cells and inhibited cell growth alone or in cooperation with imatinib mesylate (Gleevec). A mutant of BCR-ABL that is defective in transformation of myeloid cells, Tyr177Phe, was also found to be defective in raising intracellular ROS levels. Glucose metabolism in BCR-ABL-transformed cells is likely to be mediated by activation of the phosphatidylinositol-3'-kinase (PI3K) pathway, which is regulated through this site. Inhibition of PI3K or mTOR led to a significant decrease in ROS levels. Overall, our results suggest that elevated levels of ROS in BCR-ABL-transformed cells are secondary to a transformation-associated increase in glucose metabolism and an overactive mitochondrial electron transport chain and is specifically regulated by PI3K. Finally, these results hint at novel targets for drug development that may aid traditional therapy.
Similar articles
- Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A. Burchert A, et al. Leukemia. 2005 Oct;19(10):1774-82. doi: 10.1038/sj.leu.2403898. Leukemia. 2005. PMID: 16136169 - BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
Sheng Z, Ma L, Sun JE, Zhu LJ, Green MR. Sheng Z, et al. Blood. 2011 Sep 8;118(10):2840-8. doi: 10.1182/blood-2010-12-322537. Epub 2011 Jun 29. Blood. 2011. PMID: 21715304 Free PMC article. - Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway.
Naughton R, Quiney C, Turner SD, Cotter TG. Naughton R, et al. Leukemia. 2009 Aug;23(8):1432-40. doi: 10.1038/leu.2009.49. Epub 2009 Mar 19. Leukemia. 2009. PMID: 19295548 - Mechanisms of transformation by the BCR/ABL oncogene.
Sattler M, Griffin JD. Sattler M, et al. Int J Hematol. 2001 Apr;73(3):278-91. doi: 10.1007/BF02981952. Int J Hematol. 2001. PMID: 11345193 Review. - Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
Nimmanapalli R, Bhalla K. Nimmanapalli R, et al. Curr Opin Oncol. 2002 Nov;14(6):616-20. doi: 10.1097/00001622-200211000-00005. Curr Opin Oncol. 2002. PMID: 12409651 Review.
Cited by
- Gallic Acid Enhances the Efficacy of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia through Inhibition of Mitochondrial Respiration and Modulation of Oncogenic Signaling Pathways.
Xiang W, Sng C, Lam YH, Kok ZH, Linn YC, Neo SY, Siew YY, Singh D, Koh HL, Chuah C. Xiang W, et al. Int J Mol Sci. 2024 Jul 21;25(14):7958. doi: 10.3390/ijms25147958. Int J Mol Sci. 2024. PMID: 39063200 Free PMC article. - Glucose increases proliferation and chemoresistance in chronic myeloid leukemia via decreasing antioxidant Properties of ω-3 polyunsaturated fatty acids in the presence of Iron.
Shahraki S, Bahraini F, Mesbahzadeh B, Sayadi M, Sajjadi SM. Shahraki S, et al. Mol Biol Rep. 2023 Dec;50(12):10315-10324. doi: 10.1007/s11033-023-08891-7. Epub 2023 Nov 16. Mol Biol Rep. 2023. PMID: 37971569 - Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia.
Zhong FM, Yao FY, Yang YL, Liu J, Li MY, Jiang JY, Zhang N, Xu YM, Li SQ, Cheng Y, Xu S, Huang B, Wang XZ. Zhong FM, et al. Cancer Cell Int. 2023 Apr 6;23(1):61. doi: 10.1186/s12935-023-02905-x. Cancer Cell Int. 2023. PMID: 37024911 Free PMC article. - mTORC1 beyond anabolic metabolism: Regulation of cell death.
Zhu J, Wang H, Jiang X. Zhu J, et al. J Cell Biol. 2022 Dec 5;221(12):e202208103. doi: 10.1083/jcb.202208103. Epub 2022 Oct 25. J Cell Biol. 2022. PMID: 36282248 Free PMC article. Review. - The DNA repair function of BCL11A suppresses senescence and promotes continued proliferation of triple-negative breast cancer cells.
Vickridge E, Faraco CCF, Tehrani PS, Ramdzan ZM, Rahimian H, Leduy L, Gingras AC, Nepveu A. Vickridge E, et al. NAR Cancer. 2022 Sep 28;4(4):zcac028. doi: 10.1093/narcan/zcac028. eCollection 2022 Dec. NAR Cancer. 2022. PMID: 36186110 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous